# Noom's GLP-1Rx Program Combines Medication With Behavioral Coaching
Noom Med has launched GLP-1Rx, a weight-loss program that pairs glucagon-like peptide-1 medications with behavioral support from the company's established coaching model. The program addresses a gap in how GLP-1 medications are typically prescribed and used.
GLP-1 drugs like semaglutide and tirzepatide work by regulating appetite and blood sugar. They have become popular for weight management, but many people using them lack structured guidance on lifestyle changes that maximize results. Noom's approach integrates its psychology-based weight-loss methodology with medical oversight, positioning medication as one component of a broader wellness strategy rather than a standalone solution.
The program appears designed to support users through the practical challenges of GLP-1 therapy. People taking these medications often experience side effects like nausea and digestive changes. Behavioral coaching can help users navigate these effects, adjust eating patterns, and develop sustainable habits alongside medication use. This combination addresses a common pitfall: people who lose weight on GLP-1 drugs alone sometimes regain it after stopping the medication if they haven't built lasting behavioral changes.
The emphasis on customization reflects how individual responses to GLP-1 medications vary. Dosing needs differ based on weight, metabolism, and medical history. Pairing this with personalized coaching acknowledges that pharmaceutical intervention works best when paired with individual support and monitoring.
Noom's entry into telehealth GLP-1 prescribing places it alongside competitors like Ro and Calibrate Health, which also offer medications plus coaching. The company's existing base of users familiar with its behavioral app gives it a structural advantage for integrating medication management with habit tracking.
For consumers, the GLP-1Rx program offers a more comprehensive